RBM 39 targeting therapeutic (Recursion Pharmaceuticals)
- Generic Name
- RBM 39 targeting therapeutic (Recursion Pharmaceuticals)
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- UnresectableLocally AdvancedMetastatic CancersRelapsed/Refractory Lymphomas
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06678659
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸SCRI Oncology Partners - PPDS, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath